Verastem, Inc. (LON: 0LOV)

Market Cap	205.83M
Revenue (ttm)	7.46M
Net Income (ttm)	-69.73M
Shares Out	n/a
EPS (ttm)	-2.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,051
Average Volume	12,285
Open	5.40
Previous Close	5.45
Day's Range	5.24 - 5.46
52-Week Range	4.45 - 15.12
Beta	n/a
RSI	53.86
Earnings Date	Mar 14, 2025

About Verastem

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2010
• Employees: 73
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LOV

Financial Performance

Financial numbers in USD